Pharmeasy Unlisted Share Prices
PharmEasy (API Holdings Ltd)
INE0DJ201029
Listing Status: DRHP Not Filed
About Pharmeasy Unlisted Share Prices
Overview of Pharmeasy Unlisted Share Prices
PharmEasy is a consumer healthcare “super app” that provides consumers with on-demand, home delivered access to a wide range of prescription, OTC pharmaceutical, other consumer healthcare products, comprehensive diagnostic test services, and teleconsultations thereby serving their healthcare needs.
API Holdings Ltd aka Pharmeasy is India’s largest digital healthcare platform (based on GMV of products and services sold for the year ended March 31, 2021), according to RedSeer Report.
Pharmeasy operate an integrated, end-to-end business that aims to provide solutions for the healthcare needs of consumers across the following critical stages -
A. providing digital tools and information on illness and wellness,
B. offering teleconsultation,
C. offering diagnostics and radiology tests, and
D. delivering treatment protocols including products and devices
Product Offerings
- Healthcare
- Personal Care
- Healthcare devices
- Health Food & Drinks
- Accessories & Wearables
- Home Care
Timeline
2015: PharmEasy was founded by Dharmil Sheth and Dhaval Shah in Mumbai, India
2016: Raised $5 million in Series A funding led by Bessemer Venture Partners
2017: Secured $18 million in two rounds of Series B funding from Bessemer Venture Partners
2018: Raised $77.23 million across two Series C funding rounds from Eight Roads Ventures India, F-Prime Capital
2019: Raised $220 million in Series D funding from Temasek Holdings
2020: Merger of Medlife with PharmEasy
2021:
- PharmEasy acquired a 66.1% stake in Thyrocare for ₹4,546 crore ($620 million)
- Acquired a majority stake in healthcare supply chain company Aknamed
- Raised $500 million in Series F funding
- Completed a Pre-IPO round of $354 million
- Received additional private equity funding from VestinWolf Capital Management
- Filed for an initial public offering (IPO) of ₹6,250 crore ($843.46 million)
2022: PharmEasy withdrew its IPO plans and went with rights issue
Management
Siddharth Shah: Co-Founder, Managing Director and Chief Executive Officer
- He holds a bachelor’s degree in computer engineering from the Dwarakadas J. Sanghavi College, Mumbai
- Post graduate diploma in management from the Indian Institute of Management, Ahmedabad
- He was associated with Ascent Health and Wellness Solutions Private Limited as its managing director
Dharmil Sheth: Co-Founder and Whole-time Director
- Bachelor’s degree in electronics engineering from the K.J. Somaiya College of Engineering, University of Mumbai
- Post graduate diploma degree in management (marketing) from the Institute of Management Technology, Ghaziabad.
- He was associated with MakeMyTrip (India) Private Limited as a part of the online products team
- 91Streets Media Technologies Private Limited as director and co-founder.
Dr. Dhaval Shah: Co-Founder
- Post graduate diploma in management from XLRI, Xavier School of Management, Jamshedpur, Jharkhand
- MBBS degree certificate from the Maharashtra University of Health Sciences, Nashik
- McKinsey and Company Inc. as a consultant
- Associated with 91Streets Media Technologies Private Limited as an executive director
Harsh Parekh: Co-Founder and Whole-time Director
- Master’s degree in business administration from the School of Business Management, Narsee Monjee Institute of Management Studies, Mumbai
- Chief Operations Officer of Ascent Health and Wellness Solutions Private Limited
Hardik Dedhia: Co-Founder
- He joined Ascent Health and Wellness Solutions Private Limited
- Bachelor’s degree in electronics and telecommunication engineering from the University of Mumbai, Maharashtra
- Master’s degree in electrical and computer engineering from the Carnegie Mellon University, Pennsylvania
Insights of Pharmeasy Unlisted Share Prices
Financial Insight
In Crs
Particulars | 31st March, 2023 | 31st March, 2022 |
Revenue | 6700 | 5781 |
EBITDA | -1365 | -2300 |
PBT | -5197 | -3971 |
PAT | -5212 | -3993 |
Market Share
Marquee Investors
- Naspers Ventures BV
- Macritchie Investments Pte Ltd
- TP G Growth V SF Markets Pvt Ltd
IPO Updates
API Holdings, the parent company of online pharmacy start-up PharmEasy, on Monday received approval from Sebi to raise Rs 6,250 crore through an initial public offering (IPO).
Pharmeasy was last valued at $5.6 billion (Rs 42,197.79 crore) in a Rs 2,635.22-crore pre-IPO round in October 21.
Key Highlights
On 29 November 2021 API Holding Limited issue equity shares of FV Rs 1 per shares @ 4.20 per shares (Details are given below)
Industry Outlook
The Indian e-pharma industry is experiencing explosive growth, with a projected CAGR ranging from 44% to 63%.
Here's a breakdown of the promising outlook with specific figures:
Market size: The e-pharmacy market in India was valued around $512 million in 2018 and is expected to reach anywhere from $3.6 billion by 2022 to $4.5 billion by 2025.
Revenue growth: E-pharmacies are expected to see their revenue grow at a significant rate, with estimates suggesting a 54% CAGR over the next 4 years.
This translates to capturing around 5% of the total pharmaceutical sector revenue. These figures paint a bright picture for e-pharma companies like PharmEasy. The industry is attracting significant investment, with funding of $700 million secured in 2020 alone.
Recent Funding
PharmEasy's parent company, API Holdings, secured its most recent funding in April 2024.
Amount raised: $216 million (Rs 1,804 crore)
Investors: The round was led by Manipal Education and Medical Group (MEMG) along with participation from existing investors like Prosus, Temasek, and 360 One.Impact:
This funding came with a significant valuation drop of around 90% compared to PharmEasy's peak valuation of $5.6 billion in 2021. The current valuation is estimated to be around $710 million.
Listed Subsidiaries
API Holdings is a holding company that owns 71.18% of Thyrocare Technologies Ltd, making Thyrocare Technologies Ltd a subsidiary of API Holdings.
API Holdings owns 3,76,56,092( AS PER BALANCE SHEET FY 22-23) equity shares of Thyrocare Technologies Ltd, and the current market price (CMP) of the share is 751,(AS ON 24/07/2024) equivalent to 2827.9 Crores
Financial Charts of Pharmeasy Unlisted Share Prices
Balance Sheet of Pharmeasy Unlisted Share Prices
Profit and Loss of Pharmeasy Unlisted Share Prices
Ancillary of Pharmeasy Unlisted Share Prices
Ratio Analysis
Peers
Industry Benchmarking
Segment Revenue
Subsidaries
Security Allotment
Corporate Governance
Team Management Details
FAQs of Pharmeasy Unlisted Share Prices
-
How to buy PharmEasy (API Holdings Ltd)?
Below are three ways through which you can purchase PharmEasy (API Holdings Ltd):
- We at Altius Investech have many actively traded scripts and are market makers of unlisted shares. To check out all the unlisted shares traded. (Click on link). To submit a request to buy PharmEasy (API Holdings Ltd), please click on the trade button at the top of this page
- Additionally, you can download our app from your play store or app store, register on our application, and engage in active trading there.
Download the Altius App here https://onelink.to/hf4m72 - You can also reach out to us at : +91 8240614850 / +91 8240861716
-
How to sell PharmEasy (API Holdings Ltd)?
Below are three ways through which you can sell PharmEasy (API Holdings Ltd):
- We at Altius Investech have many actively traded scripts and are market makers of unlisted shares. To check out all the unlisted shares traded. (Click on link). To submit a request to sell PharmEasy (API Holdings Ltd), please click on the trade button at the top of this page
- Additionally, you can download our app from your play store or app store, register on our application, and engage in active trading there.
Download the Altius App here https://onelink.to/hf4m72 - You can also reach out to us at : +91 8240614850 / +91 8240861716
-
What is the price of PharmEasy (API Holdings Ltd)?
We provide a two way quote on all the shares we deal in. Your buy price for PharmEasy (API Holdings Ltd) is ₹8.1 and your sell price for PharmEasy (API Holdings Ltd) is ₹7.5. The price is based on our estimates and market conditions.
-
What is the lock-in period of PharmEasy (API Holdings Ltd)?
The lock-in period for PharmEasy (API Holdings Ltd) varies depending on the category of investors:
- For retail Investors, HNIs, or Body Corporates, the lock-in period is 6 months from the date of the listing of PharmEasy (API Holdings Ltd)
- For Venture Capital Funds or Foreign Venture Capital Investors, there is a lock-in period of 6 months from the date of acquisition of PharmEasy (API Holdings Ltd)
- For AIF-II (Alternative Investment Funds - Category II), there is no lock-in period
August 2021 saw the introduction of this regulation by SEBI. The purpose of the regulation change, which lowered the lock-in period from a year to six months, was to incentivize additional investments in firms getting ready for initial public offerings, or IPOs. Since its introduction, a number of Portfolio Management Services (PMS) have advised their clients to purchase Pre-IPO shares in order to take advantage of the advantages associated with early-stage investments. This reduction in the lock-in period is considered as a significant step forward.
-
How is the PharmEasy (API Holdings Ltd) price calculated?
Fundamental & Comparative valuation models and the forces of demand and supply in the market for unlisted shares dictate the price. These prices are based on our estimates and transaction history of PharmEasy (API Holdings Ltd). The price is also determined from the most recent funding round for PharmEasy (API Holdings Ltd). This provides us with a benchmark valuation, offering a clear indication of the company's current market value as perceived by investors and industry experts.
-
What are the lot sizes of PharmEasy (API Holdings Ltd)?
We can generally arrange lot sizes starting with an investment of INR 20,000. To confirm the lot sizes of PharmEasy (API Holdings Ltd) with us kindly click here.
-
What are the financials of PharmEasy (API Holdings Ltd)?
The financials of PharmEasy (API Holdings Ltd) which includes the P/L of PharmEasy (API Holdings Ltd) and the Balance Sheet of PharmEasy (API Holdings Ltd) is in the financials section (Click on link).
-
Where can I find the annual report of PharmEasy (API Holdings Ltd)?
The annual report of PharmEasy (API Holdings Ltd) is available in the annual report section (Click on link).
-
Is buying PharmEasy (API Holdings Ltd) legal in India?
Yes, buying and selling unlisted shares in India is indeed 100% legal. This activity is regulated and governed under the guidelines provided by the Securities and Exchange Board of India (SEBI). Investors and traders must adhere to these regulations and guidelines to ensure compliance with legal and financial standards. It's important for participants in the unlisted share market to be aware of and understand these regulations to engage in transactions legally and securely.
-
Short-term Capital Gain taxes to be paid on PharmEasy (API Holdings Ltd)?
When you sell unlisted shares within a period of two years from the date of acquisition, any profit earned from the sale is classified as Short-term Capital Gain (STCG). This gain is then added to your total income for that financial year. The tax on this short-term capital gain is calculated based on your applicable individual income tax slab rates. Therefore, the rate at which you will pay tax on the STCG from unlisted shares depends on your total income, including this gain, and the tax slab it falls under as per the prevailing income tax laws in India. It's important for investors to consider these tax implications when engaging in transactions involving unlisted shares.
-
Long-term Capital Gain taxes to be paid on PharmEasy (API Holdings Ltd) and how are They Taxed?
Long-term Capital Gains (LTCG) on unlisted shares in India refer to the profits earned from the sale of unlisted shares that have been held for more than two years. The key aspects of LTCG on unlisted shares include:
- Tax Rate: LTCG on unlisted shares is taxed at a rate of 20%.
- Indexation Benefit: This is a significant advantage for investors. Indexation allows for adjusting the purchase price of the shares for inflation, which can reduce the taxable gain.
- Importance for Investors: Understanding LTCG is crucial, especially for High Net-worth Individuals (HNIs) and retail investors, as it impacts their investment strategy and tax planning. Knowing these details helps in making informed investment decisions.
- Calculation: LTCG is calculated by subtracting the indexed cost of acquisition (the purchase price adjusted for inflation) from the sale price of the shares. The profit thus calculated is subject to a 20% tax.
- Applicability: LTCG tax is applicable to profits from the sale of unlisted shares held for more than two years.
- Relevance: This tax is particularly relevant to investors in the unlisted share market, including those considering selling their holdings after a period of more than two years.
-
Applicability of Taxes on PharmEasy (API Holdings Ltd) once it is listed?
When shares initially bought in the unlisted market become listed, the taxation rules change significantly if these shares are sold through a stock exchange. Here's what investors need to know:
Transition to Listed Market Tax Rates: Once unlisted shares are listed on the stock exchange and subsequently sold, the tax rates applicable to listed securities come into effect. This shift means that the favourable tax treatments for listed shares, as per the prevailing tax laws, will apply.
Taxation Based on Holding Period: The crucial factor in determining the type of capital gains tax (Long-term or Short-term) is the holding period of the shares. Importantly, this period is calculated from the original purchase date when the shares were unlisted.
Long-term vs. Short-term Capital Gains: If the shares are sold after being held for more than one year from the date of purchase (including the period when they were unlisted), they are subject to Long-term Capital Gains (LTCG) tax.
Conversely, if sold within one-year, Short-term Capital Gains (STCG) tax rates apply.
Significance for Investors: This information is vital for investors in the unlisted market, as it impacts their tax planning and decision-making process. Understanding these nuances ensures that investors can strategically plan the sale of their shares post-listing to optimize tax implications.
Advice for Investors: It's advisable for investors to keep a record of their purchase dates and monitor the listing dates closely. Additionally, staying updated with the latest tax regulations or consulting with a financial advisor is recommended for accurate tax calculations and compliance. -
How does Altius Investech source PharmEasy (API Holdings Ltd)?
At Altius Investech, our approach to sourcing Boat Unlisted Share (Imagine Marketing) involves a strategic and direct method. Primarily, we acquire these shares from the below key groups:
Employees of the Company: Employee stock option plans (ESOPs) or other compensation packages frequently include shares for firm employees. For a various reasons, such as including portfolio diversification or financial considerations, some of these employees may eventually choose to sell their shares. We engage with these employees, providing them a platform to sell their shares.
Initial Investors: These are the angel or early-stage investors who provided capital to the business in its early stages. These original investors may look to sell all or part of their ownership position in the company as it develops and flourishes. This might be done for various reasons such as in order to maximise their investment, reallocate resources, or make other calculated financial decisions.
Funding rounds and VC funds: Altius Investech sources the shares from private placement rounds in which private companies seek to obtain capital from the market. Through our platform, venture capital funds can liquidate their shares and we receive the inventory from them when they decide to sell a portion of their ownership through block trades.
By establishing connections with these groups, Altius Investech guarantees our clients a steady and dependable supply of Boat Unlisted Share (Imagine Marketing). This process not only makes it easier for employees and initial investors in liquidating their assets, but it also gives our clients access to shares that aren't often found on the open market. Our platform effectively facilitates a win-win situation for both buyers and sellers. -
How to trust Altius Investech before buying PharmEasy (API Holdings Ltd) from its platform?
Altius Investech stands at being India's fastest growing and leading marketplace for buying and selling unlisted shares. We believe in enabling access to alternative sources of investments at lower entry barriers to private equity investments.
With more than 25 years of experience, Altius Investech has carved a niche in the financial market by serving more than 8000 clients. The incredible journey is further highlighted by the vast number of transactions that Altius Investech has facilitated transactions that have already exceeded 300 crores.
For investors Altius Investech curates investment opportunities in companies at reasonable valuations which are on the verge of an IPO leading to massive value unlocking. Investments are backed by thorough research and sound investment thesis, with a time bound exit plan.
For ESOP Shareholder and existing Investors, we assist them to liquidate their shares even if they are not publicly traded by creating a platform where we find the right buyers and sellers for the best prices.
Altius Investech have been featured in top media news outlets like Economic Times, Financial Express, Money control. Check out about us on these - leading publications (Click on link) Our journey over these years has not just been about numbers; it's been about building trust and reliability.
We at Altius Investech are dedicated to upholding the greatest levels of ethics and transparency, making sure that your investment experience is not only profitable but also safe and reliable.
Press of Pharmeasy Unlisted Share Prices
Featured Blogs of Pharmeasy Unlisted Share Prices
Company Information of Pharmeasy Unlisted Share Prices
Stay Connected.
Registered Address
73A, GC Avenue, Kolkata -13Corporate Address
Y-19, 90 DEGREES Magnus, EP Block,Sec V, Kolkata 700091Chennai Office
19/10, Guru Vappa Chetty Street, Chintadripet, Chennai - 600002
Dubai Office
2701, Executive Tower G, Business Bay, Dubai, UAE
Andhra Pradesh & Telangana Office
54-19-25/1, Flat no.101, Sai Residency, Nelson Mandela Park Road, LIC Colony, Vijayawada (Urban), Andhra Pradesh - 520008Altius Investech